METFORMIN — Pharmacology Drug Monograph

Current metformin pharmacology guide covering FDA-approved uses, mechanism of action, pharmacokinetics, dosage, adverse effects, interactions, monitoring and safety.

What Is Metformin?

Metformin is an oral biguanide antihyperglycemic drug used with diet and exercise to improve glycemic control in people with type 2 diabetes mellitus (T2DM). Current U.S. labeling for several metformin extended-release products includes adults and pediatric patients 10 years and older with T2DM.

Metformin primarily reduces hepatic glucose production and improves glucose utilization. Unlike insulin secretagogues, it does not directly stimulate pancreatic insulin secretion.

Metformin Quick Facts

Property	Information
Generic name	Metformin
Drug class	Biguanide
Therapeutic class	Antihyperglycemic
FDA-approved use	Type 2 diabetes mellitus
Route	Oral
Forms	Immediate-release and extended-release products
Main effect	↓ Hepatic glucose production
Metabolism	Minimal/no significant hepatic metabolism
Elimination	Primarily renal, largely unchanged
Common adverse effects	Diarrhea, nausea, vomiting, abdominal discomfort
Serious risk	Metformin-associated lactic acidosis
Long-term concern	Vitamin B12 deficiency
eGFR <30	Do not use

FDA-Approved, Off-Label and Investigational Uses

The FDA-approved indication is improvement of glycemic control in type 2 diabetes, as an adjunct to diet and exercise.

Use	Status
Type 2 diabetes	FDA-approved
Prediabetes	Not FDA-approved
Polycystic ovary syndrome	Not FDA-approved
Weight-loss treatment	Not FDA-approved
Cancer treatment/prevention	Investigational
Anti-aging/longevity	Investigational

Metformin is being studied for effects beyond diabetes, including cancer, aging, inflammation and neurodegenerative disease, but these research areas should not be presented as established FDA-approved indications. Recent reviews continue to describe these applications as areas of investigation.

Mechanism of Action

Metformin has a multifactorial mechanism of action. Its glucose-lowering effects include:

• Decreased hepatic gluconeogenesis and glucose production
• Increased peripheral glucose utilization
• Improved insulin sensitivity
• Effects on intestinal glucose handling

AMP-activated protein kinase (AMPK) contributes to some metformin effects, but the mechanism is more complex than simple AMPK activation. Recent pharmacology reviews describe AMPK-dependent and AMPK-independent mechanisms involving mitochondrial function, hepatic metabolism, skeletal muscle and intestinal pathways.

High-yield pathway:
Metformin → ↓ hepatic glucose production + ↑ glucose utilization → ↓ blood glucose

Pharmacodynamics

Metformin lowers fasting and postprandial blood glucose without directly increasing insulin secretion. Its overall effect reflects actions in several tissues, particularly the liver, intestine and skeletal muscle.

Because it does not directly stimulate insulin release, metformin has a relatively low intrinsic risk of hypoglycemia when used alone. Hypoglycemia can become more likely when it is combined with insulin or insulin secretagogues.

Pharmacokinetics

Metformin has an oral bioavailability generally reported around 40–60%. It is not significantly metabolized by the liver and is predominantly eliminated through the kidneys. Its elimination is therefore strongly affected by renal function.

The drug has limited plasma protein binding and is eliminated largely unchanged. Renal impairment can increase metformin exposure and prolong elimination.

Dosage and Formulations

Metformin is available in immediate-release and extended-release oral formulations.

For one current extended-release U.S. label, the recommended starting dose is 500 mg once daily with the evening meal, increased by 500 mg weekly according to response and tolerability, up to 2,000 mg once daily. Tablets should be swallowed whole.

Immediate-release products have different dosing schedules and may have a labeled maximum total daily dose of 2,550 mg. Product-specific prescribing information should always be checked before clinical use.

Renal Function and Contraindications

Renal function is particularly important because metformin is substantially eliminated by the kidneys.

• eGFR ≥45: Treatment may generally be continued according to labeling and clinical circumstances.
• eGFR 30–45: Initiation is not recommended; continuation requires benefit-risk assessment.
• eGFR <30: Metformin should not be used.

Major contraindications include severe renal impairment, metabolic acidosis including diabetic ketoacidosis, and hypersensitivity to metformin.

Adverse Effects

The most common adverse effects are gastrointestinal:

• Diarrhea
• Nausea
• Vomiting
• Flatulence
• Abdominal discomfort

Long-term therapy can be associated with vitamin B12 deficiency, making B12 assessment relevant when clinically indicated.

The most serious recognized toxicity is metformin-associated lactic acidosis, a rare but potentially life-threatening condition. Risk increases particularly with significant renal impairment and other conditions that promote metformin accumulation or impaired lactate handling.

Drug Interactions

Important interaction considerations include:

• Cationic drugs: Some renally eliminated cationic medicines can increase metformin exposure.
• Carbonic anhydrase inhibitors: May increase the risk of metabolic acidosis.
• Insulin/insulin secretagogues: May increase hypoglycemia risk.
• Iodinated contrast: Metformin may need to be temporarily discontinued in specified patients and procedures.

Current U.S. labeling specifically recommends attention to renal function around iodinated contrast procedures.

Monitoring

Key monitoring parameters include:

1. eGFR/renal function
2. Blood glucose
3. HbA1c
4. Vitamin B12 when appropriate
5. Gastrointestinal tolerability
6. Clinical factors associated with lactic acidosis

For patients taking metformin, current labeling recommends obtaining eGFR before treatment and at least annually, with more frequent assessment in patients at increased risk of renal impairment.

Special Populations

Children: Certain U.S. formulations are approved for patients aged 10 years and older with T2DM.

Older adults: Renal function requires particular attention because kidney function may decline with age.

Renal impairment: Reduced kidney function substantially affects metformin clearance and safety.

Pregnancy and lactation: Use should be evaluated using current product labeling and individualized clinical assessment.

Clinical Evidence and Current Research

Metformin has decades of clinical evidence supporting its glucose-lowering efficacy in T2DM. Current research continues to examine its molecular effects on mitochondrial metabolism, intestinal signaling, glucose disposal and other metabolic pathways. A 2026 review emphasizes that metformin’s pharmacology involves multiple tissue-specific mechanisms rather than a single molecular target.

Recent experimental research has also identified intestinal mitochondrial complex I inhibition as a potential contributor to metformin’s glucose-lowering effects, demonstrating how understanding of this established drug continues to evolve.

Regulatory Status

Metformin remains an FDA-approved oral antihyperglycemic medicine for type 2 diabetes mellitus. Current U.S. labeling was updated for some extended-release products in 2026, including indications and dosing information.

Because multiple manufacturers and formulations exist, researchers and healthcare professionals should consult the specific current product label rather than assuming that all metformin products have identical labeling.

High-Yield Student Points

• Class: Biguanide
• Main indication: Type 2 diabetes
• Main action: ↓ hepatic glucose production
• Mechanism: Multifactorial; AMPK is involved but is not the complete explanation
• Elimination: Mainly renal
• Common ADRs: GI disturbances
• Serious toxicity: Lactic acidosis
• Long-term concern: Vitamin B12 deficiency
• eGFR <30: Do not use
• eGFR 30–45: Do not initiate
• Hypoglycemia: Low intrinsic risk as monotherapy

FAQs

Is metformin FDA-approved for weight loss?

No. Weight loss is not an FDA-approved indication for metformin.

Is metformin FDA-approved for PCOS?

No. PCOS is not an FDA-approved indication in the United States.

What is the main mechanism of metformin?

It primarily reduces hepatic glucose production and improves peripheral glucose utilization and insulin sensitivity.

Is metformin metabolized by the liver?

Metformin undergoes little to no significant hepatic metabolism and is primarily eliminated by the kidneys.

What is the most important safety issue?

Metformin-associated lactic acidosis is the major serious safety concern, particularly in patients with significant renal impairment.

Related Drugs

• Sulfonylureas
• DPP-4 inhibitors
• SGLT2 inhibitors
• GLP-1 receptor agonists
• Thiazolidinediones
• Insulin
• Other antihyperglycemic drugs